Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money.
Today we look at two noteworthy recent insider buys.
On Wednesday, Neoleukin Therapeutics' CEO, Jonathan G.
Drachman, made a $933,550 purchase of NLTX, buying 150,000 shares at a cost of $6.22 a piece.
So far Drachman is in the green, up about 22.1% on their purchase based on today's trading high of $7.60.
Neoleukin Therapeutics Inc is trading up about 18.6% on the day Friday.
And at Cyxtera Technologies, there was insider buying on Wednesday, by Director Gregory L.
Waters who bought 93,570 shares at a cost of $8.39 each, for a total investment of $785,464.
Cyxtera Technologies is trading trading flat on the day Friday.